✦ LIBER ✦

Clinical Trials of Atrasentan in Hormone-Refractory Prostate Cancer

✍ Scribed by Lee, David; Sartor, Oliver

Book ID: 118627009
Publisher: CIG Media Group, LP.
Year: 2003
Tongue: English
Weight: 161 KB
Volume: 2
Category: Article
ISSN: 1540-0352
DOI: 10.1016/s1540-0352(11)70025-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bone alkaline phosphatase & extent of sk

Bone alkaline phosphatase & extent of skeletal disease burden in a clinical trial of atrasentan are predictive of clinical disease progression in hormone refractory prostate cancer

✍ C. Schulman; R. Padley; M. Weinberg; J. Schmitt 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 342 KB

Atrasentan clinical trials discontinued

Atrasentan clinical trials discontinued in endstage prostate cancer

📂 Article 📅 2003 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Phase 3, randomized, controlled trial of

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

✍ Joel B. Nelson; William Love; Joseph L. Chin; Fred Saad; Claude C. Schulman; Dar 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 244 KB 👁 2 views

Clinical pharmacology of an atrasentan a

Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer

✍ Younis, Islam R.; George, Daniel J.; McManus, Terence J.; Hurwitz, Herbert; Cree 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 299 KB

Atrasentan: The First Endothelin Recepto

Atrasentan: The First Endothelin Receptor Antagonist for Hormone-Refractory Prostate Cancer

✍ Claude Schulman 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 384 KB

617 Atrasentan delays disease progressio

617 Atrasentan delays disease progression in men presenting with metastatic hormone refractory prostate cancer

✍ C. Schulman; D. Dearnaley; B. Zonnenberg; L. Coetzee; S. Hulting; J. Isaacson; A 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 212 KB